Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results

Abstract

A new oral contraceptive with a novel estrogen, estetrol, combined with drospirenone has efficacy and safety within the range of other available oral contraceptives. Large phase 4 studies will be needed to confirm if this combination is associated with an improved adverse event profile or lower thrombosis risk.